🧠 Carbidopa prevents the breakdown of levodopa so that more is able to cross the blood-brain barrier is correct because carbidopa blocks peripheral decarboxylase enzymes, allowing more active levodopa to reach the brain where dopamine is needed.

🧠 I used the brain emoji because this medication works specifically to improve brain dopamine levels, which is the central problem in Parkinson’s disease.

🧠 Levodopa is easily broken down in the peripheral bloodstream before it reaches the brain. Carbidopa inhibits the enzyme responsible for this early breakdown, allowing higher concentrations of levodopa to cross the blood–brain barrier and be converted to dopamine in the central nervous system.

🧠 This increases therapeutic effect while reducing the amount of levodopa wasted in the bloodstream.

🧠 Carbidopa also reduces peripheral dopamine side effects like nausea and vomiting because less levodopa is converted outside the brain.

🧠 Carbidopa minimizes drug interactions that occur with levodopa alone is incorrect because the main purpose of carbidopa is not to reduce interactions but to prevent peripheral breakdown.

🧠 Carbidopa allows for larger doses of levodopa to be given is incorrect because the goal is actually the opposite—to allow smaller doses of levodopa while achieving stronger effects.

🧠 Carbidopa reduces the adverse effects of levodopa is partially true but not the primary purpose. It reduces nausea, vomiting, and orthostatic hypotension because it prevents peripheral conversion—this is a secondary effect.